



CSE: COOL  
OTC: CLABF  
Frankfurt: LD6, WKN: A3CSSU

## **CORE ONE LABS' ANNOUNCES CHANGE OF AUDITOR**

**Vancouver, British Columbia, Canada** – September 29, 2022 – **Core One Labs Inc.** (CSE: **COOL**), (OTC: **CLABF**), (Frankfurt: **LD6**, WKN: A3CSSU) (the "**Company**" or "**Core One**") announces that its auditor, Dale Matheson Carr-Hilton Labonte LLP (the "**Former Auditor**") has resigned effective September 15, 2022. As of the date hereof, the Company has not yet appointed a successor auditor.

The matter is currently under review by the Company's audit committee and discussions have been ongoing with potential successor auditors to fill the vacancy as required under National Instrument 51-102 – *Continuous Disclosure Obligations* ("**NI 51-102**").

The Former Auditor's reports on the consolidated financial statements of the Company for the years ended December 31, 2021, and December 31, 2020, did not express a modified opinion and the Former Auditor has confirmed there have been no "reportable events" as defined in NI 52-102. The Company is complying with the requirements of NI 51-102 in respect of the Former Auditor's resignation and the change of auditor notice (the "**Notice**"), and the Former Auditor's response are available on SEDAR.

As soon as a successor auditor to the Former Auditor has been appointed, the Company will file a further press release confirming such appointment and the successor auditor's written response as to whether it agrees with the statements in the Notice is expected to be filed on SEDAR shortly thereafter.

### **About Core One Labs Inc.**

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the "technology") which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

### **Core One Labs Inc.**

Joel Shacker  
Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com  
1-866-347-5058



CSE: COOL  
OTC: CLABF  
Frankfurt: LD6, WKN: A3CSSU

**Cautionary Disclaimer Statement:**

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the *Controlled Drugs and Substances Act* (Canada) and it is a criminal offence to possess substances under the *Controlled Drugs and Substances Act* (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.